Transgene Biotek

Which are the latest news on Transgene Biotek?

Why is Transgene Biotek Ltd falling/rising?

As of 09-Aug, Transgene Biotek Ltd's stock price is at 2.91, unchanged from the previous day, but it has been on a downward trend with a total decline of 7.35% over the last three days and significant drops over longer periods. The stock is trading below its moving averages, indicating a bearish trend, and has a year-to-date decline of 7.62%.

As of 09-Aug, Transgene Biotek Ltd's stock price is currently at 2.91, showing no change from the previous day. However, the stock has been experiencing a downward trend, having underperformed the sector by 1.13% today and falling consecutively for the last three days, resulting in a total decline of 7.35% during this period. Over the past week, the stock has decreased by 3.32%, and it has also shown significant declines over longer periods, including a 9.35% drop in the last month and a 38.61% decrease over the past year.<BR><BR>Additionally, Transgene Biotek is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite a rise in delivery volume by 18.96% against the 5-day average, the overall performance and historical returns suggest that investor sentiment remains negative. The stock's year-to-date performance shows a decline of 7.62%, which is slightly better than the Sensex's decline of 7.89%, but still reflects a challenging environment for the company. Overall, these factors contribute to the stock's current falling trend.

When is the next results date for Transgene Biotek Ltd?

The next results date for Transgene Biotek Ltd is 07 August 2026.

The next results date for Transgene Biotek Ltd is scheduled for 07 August 2026.

How big is Transgene Biotek?

As of 10th June, Transgene Biotek Ltd has a market capitalization of 24.00 Cr and reported Net Sales of 0.20 Cr with a Net Profit loss of 1.65 Cr over the latest four quarters. Shareholder's Funds are valued at 10.03 Cr, while Total Assets amount to 144.09 Cr.

As of 10th June, Transgene Biotek Ltd has a market capitalization of 24.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.20 Cr. However, it experienced a Net Profit loss of 1.65 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 10.03 Cr, while Total Assets amount to 144.09 Cr.

Who are in the management team of Transgene Biotek?

The management team of Transgene Biotek includes K Koteswara Rao (Chairman & Managing Director), Ankita Jain (Company Secretary & Compliance Officer), and independent directors Sujana Kadiam, Santosh Kumar, and Marri Swetha.

The management team of Transgene Biotek includes the following individuals:<BR><BR>1. **K Koteswara Rao** - Chairman & Managing Director<BR>2. **Ankita Jain** - Company Secretary & Compliance Officer<BR>3. **Sujana Kadiam** - Independent Director<BR>4. **Santosh Kumar** - Independent Director<BR>5. **Marri Swetha** - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Transgene Biotek?

Transgene Biotek's peers include Centenial Surgic, Chennai Meena, Tejnaksh Health, Adeshwar Meditex, Family Care, Vanta Bioscience, Looks Health, Clinitech Lab, and Galaxy Medicare. Key highlights include Chennai Meena's highest 1-year return at 17.93% and Centenial Surgic's lowest at -39.57%, with Transgene Biotek at -27.27%.

Peers: The peers of Transgene Biotek are Centenial Surgic, Chennai Meena, Tejnaksh Health., Adeshwar Meditex, Family Care, Vanta Bioscience, Looks Health, Clinitech Lab, and Galaxy Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Galaxy Medicare, while Average management risk is found at Family Care and Adeshwar Meditex, and the rest have Below Average management risk. Good growth is noted at Family Care, while Below Average growth is seen at Centenial Surgic, Tejnaksh Health., and Vanta Bioscience, and the rest do not qualify. Good capital structure is present at Tejnaksh Health. and Clinitech Lab, Average capital structure is found at Centenial Surgic and Adeshwar Meditex, while Below Average capital structure is seen at Vanta Bioscience, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Chennai Meena at 17.93%, while the peer with the lowest is Centenial Surgic at -39.57%. Transgene Biotek's 1-year return is -27.27%, which is better than Centenial Surgic but worse than Chennai Meena. Additionally, peers with negative six-month returns include Centenial Surgic, Adeshwar Meditex, Family Care, and Vanta Bioscience.

What does Transgene Biotek do?

Transgene Biotek Ltd is a biotechnology company in India focused on research and development in vaccines, oncology, and drug delivery technologies. As of March 2026, it reported net sales and profit of 0 Cr, with a market cap of INR 24 Cr.

Overview: <BR>Transgene Biotek Ltd is a biotechnology company engaged in research and development in the healthcare services industry, specifically focusing on vaccines, oncology, and new drug delivery technologies.<BR><BR>History: <BR>Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first biotechnology companies in India. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 2.04 <BR>Return on Equity: -19.69% <BR>Price to Book: 2.73<BR><BR>Contact Details: <BR>Address: Plot No 69 & 70 IDA Bollaram, Sangareddy Telangana: 502325 <BR>Website: http://www.transgenebiotek.com

How has been the historical performance of Transgene Biotek?

Transgene Biotek has seen a rise in net sales from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25, but continues to report negative operating profits, with a loss of -1.13 Cr in Mar'25 and increasing total expenditures of 1.39 Cr. The company faces ongoing financial challenges, reflected in persistent losses before and after tax, and stagnant cash flow from operations.

Answer:<BR>The historical performance of Transgene Biotek shows a gradual increase in net sales, rising from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25. However, the company has consistently reported negative operating profits, with an operating profit of -1.13 Cr in Mar'25, indicating a worsening trend compared to -0.62 Cr in Mar'24. The total expenditure has also increased significantly, reaching 1.39 Cr in Mar'25 from 0.85 Cr in Mar'24. The profit before tax has remained negative, with a loss of -0.68 Cr in Mar'25, slightly worse than -0.66 Cr in Mar'24. The net profit after tax also reflects this trend, showing a loss of -0.68 Cr in Mar'25 compared to -0.66 Cr in Mar'24. The company's total liabilities have remained relatively stable at 142.33 Cr in Mar'24, down from 142.36 Cr in Mar'23. The cash flow from operating activities has been stagnant, with no cash inflow reported in recent years.<BR><BR>Breakdown:<BR>Transgene Biotek's financial performance reveals a mixed picture over the years. Net sales have shown a positive trend, increasing from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25, yet the company continues to face significant challenges with operating profits, which have remained negative, culminating in -1.13 Cr in Mar'25. The total expenditure has escalated to 1.39 Cr, contributing to a profit before tax of -0.68 Cr in Mar'25, indicating persistent financial strain. The net profit after tax mirrors this situation, with a loss of -0.68 Cr. Despite a stable total liability figure of 142.33 Cr in Mar'24, the company's cash flow from operations has not improved, reflecting ongoing operational difficulties. Overall, while there is a slight increase in sales, the underlying profitability issues and rising expenditures suggest that Transgene Biotek is still navigating a challenging financial landscape.

Who are the top shareholders of the Transgene Biotek?

The top shareholder of Transgene Biotek is Dr. K Koteswara Rao, holding 21.89% of shares, while individual investors collectively own 71.88%. There are no institutional shareholders, mutual fund schemes, or pledged promoter holdings.

The top shareholders of Transgene Biotek include Dr. K Koteswara Rao, who holds the largest share at 21.89%. The majority of the company's shares are held by individual investors, accounting for 71.88% of the total holdings. There are no institutional shareholders or mutual fund schemes involved, and there are no pledged promoter holdings. The highest public shareholder is categorized as "Other Shr Off Family," but they hold 0%. Overall, the shareholding structure indicates a strong presence of individual investors in the company.

Is Transgene Biotek overvalued or undervalued?

As of April 25, 2023, Transgene Biotek is considered risky and overvalued, with a PE ratio of -30.23 and a year-to-date return of -42.61%, significantly underperforming compared to peers and the Sensex.

As of 25 April 2023, the valuation grade for Transgene Biotek has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of -30.23, an EV to EBITDA of -39.71, and a Price to Book Value of 3.01. In comparison to peers, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals stands at 69.03, indicating that Transgene Biotek's valuation metrics are significantly weaker.<BR><BR>The company's recent performance has also been disappointing, with a year-to-date return of -42.61%, contrasting sharply with the Sensex's gain of 5.58% over the same period. This underperformance, coupled with negative returns over various time frames, reinforces the conclusion that Transgene Biotek is overvalued in the current market environment.

What is the technical trend for Transgene Biotek?

As of May 14, 2025, Transgene Biotek's technical trend is mildly bearish, with mixed signals across various indicators showing a shift from bearish to mildly bullish on the weekly timeframe, while remaining bearish on the monthly.

As of 14 May 2025, the technical trend for Transgene Biotek has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are showing a mildly bearish trend, and the Bollinger Bands are sideways on the weekly chart but bearish on the monthly. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory shows a mildly bullish trend on the weekly timeframe with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven by the mixed signals across different time frames and indicators.

Has Transgene Biotek declared dividend?

No Dividend History Available